ATMA CENA
All articles

Research

5 articles

Two hands reaching toward each other over rocks by the sea in black and white, evoking reaching out for help and recovery.
Industry

Treating the Disease or Opening a Learning Window? What a New Review of Psychedelics for Substance Use Disorders Means for Canadian Practitioners

A new Yale and WashU review asks whether psychedelics treat substance use disorders or open a window for learning. What it means for Canadian practitioners.

A backlit profile silhouette with a fine mist in the air, evoking intranasal administration of a short-acting psychedelic.
Industry

One Nasal Dose, Two Hours in Clinic: What the New JAMA Mebufotenin Trial Means for Canadian Practitioners

A JAMA phase 2b trial links one intranasal dose of mebufotenin (5-MeO-DMT) to lower depression scores in TRD. What it means for Canadian clinicians.

A calm therapy room with a green armchair and a leafy plant by frosted-glass windows, evoking a quiet integration conversation.
Industry

'The Start of a Process, Not the Cure': What Psychedelic Trial Participants Want Practitioners to Know

A new Frontiers in Psychiatry study asked former psychedelic trial participants what helped and what hurt. Key lessons for Canadian practitioners.

A calm clinical consultation room with two chairs and soft natural light.
Industry

One Session, One Year of Follow-Up: What a Swedish Trial Tells Practitioners About Durability

A Swedish randomized trial followed participants for a full year after a single psychedelic therapy session. What it means for practitioners.

Line illustration of a human head in profile with fading upward arrows approaching a highlighted brain region, representing reduced bottom-up signalling into the default mode network.
Industry

Three Psychedelics, One Shared Brain Signature: What a New Stanford Study Means for Practitioners

A Stanford-led PNAS study looks at how psychedelics affect signalling into the brain's default mode network. What it means for practitioners.